MedTrace Logo

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01665846 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-06-01

No results posted yet for this study

Summary

The purpose of this study is to describe the radiologic findings on brain MRI after ferumoxytol administration in HIV-infected patients with cognitive impairment.

Conditions

  • HIV Dementia

Interventions

DRUG

Ferumoxytol

A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • University of Hawaii

    lead OTHER

Principal Investigators

  • Beau K Nakamoto, MD, PhD · University of Hawaii, Hawaii Center for AIDS, John A Burns School of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01665846 on ClinicalTrials.gov